Choose a Purchase Option


Course Description

We can begin using some of the CSA principles today, even outside of the intended focus for the final guidance. This is provided that for these other areas, we are able to adequately explain their use and defend the tie-in to Part 11, data integrity, the Quality Management System (QMS) and other relevant documents and programs.

In this seminar, we’ll provide an overview of the transition process in going from CSV to CSA. We’ll then dive into a step-by-step guide for the transition that can be done by any company. The transition steps, related documents and other artifacts, and the potential issues to watch out for will be laid out very carefully.

The seminar will include a Q&A session at the end of each day. There are Appendices at the end of the slide deck that provides references related to the content that can be reviewed at your leisure. There is also a series of questions with answers provided, along with a rationale for the correct choice. Again, this can be reviewed after the event to further support the learnings from this seminar.

Why Should You Attend

Providing safe and effective pharmaceuticals, medical devices, and other FDA-regulated products is in the best interests of all those involved in the development, manufacturing, testing, and distribution of these products, as well as the customers/patients. You will learn about FDA’s CSV and CSA approaches, where the latter will enable practitioners to take advantage of newer technologies and innovations, including cloud services and Software-as-a-Service (SaaS) solutions. CSA will provide a more practical approach to testing and verification of requirements based on potential risk, should they fail to operate properly. It’s no longer a “one-size-fits-all” testing approach, as taken with CSV. CSA is also focused on critical thinking and requires some organizational change management to fully effect it in your environment

In this seminar, you will learn just how to transition your validation work from classic Computer System Validation (CSV) to Computer Software Assurance (CSA), based on the 2022 draft guidance from FDA, and now the final guidance issued in September 2025 for medical device companies, specifically in the areas of manufacturing and quality testing. You can increase efficiency and effectiveness of software development life cycle (SDLC) activities, enabling the delivery and support of computer solutions and new innovative products that will drive industry over the coming years.

You will also learn about 21 CFR Part 11 (ER/ES), data integrity, data life cycle management, and data privacy, while following a CSA approach to validation.

Finally, we will cover trends in industry and FDA related to the use of Artificial Intelligence (AI), Machine Learning (ML), and Large Language Models (LLMs), such as ChatGPT, Copilot, and Gemini, to name a few. Both industry and FDA have begun work in this area, which is currently under review to determine the appropriate regulatory framework to apply to it.

This seminar is intended for those working in the FDA-regulated industries, focused specifically on medical device companies. However, CSA principles can be used for pharmaceutical, medical device software, and tobacco products if applied carefully to ensure you have documented evidence that is defensible.

You should attend this seminar if you are responsible for planning, executing or managing the development, implementation or validation of any system governed by FDA regulations, or if you are using, maintaining, or supporting such a system. Learn by reviewing industry best practices and knowing where to gather key information to help you move forward with CSA and newer technologies and approaches quickly and in compliance with FDA.

Course Agenda

Day 01

Morning Session:

  • Computer System Validation (CSV)
  • GAMP®5 “V” Model
  • System Development Life Cycle (SDLC) methodology
  • Validation Planning

15-Minute Break

  • Validation Requirements
  • Validation Testing
  • Validation Reporting
  • Requirements Traceability Matrix (RTM)

1-Hour Lunch Break

Afternoon Session:

  • Computer Software Assurance (CSA)
  • Critical Thinking
  • GAMP®5, 2nd Edition and its alignment with CSA 
  • Transition from CSV to CSA

15-Minute Break

  • 21 CFR Part 11 Guidance (ER/ES)
  • 21 CFR Part 11 Requirements and Controls
  • Common 21 CFR Part 11 Deficiencies

15-Minute Q&A

Day 02

Morning Session:

  • Data Integrity Guidance (ALCOA+++ Principles)
  • Data Integrity Requirements and Controls
  • Common Data Integrity Deficiencies
  • Data Life Cycle Management
  • Data Governance

15-Minute Break

  • Data Privacy
  • Commercial-Off-the-Shelf (COTS) solutions
  • Cloud Services
  • Software-as-a-Service (SaaS) Solutions 
  • Platform-as-a-Service (PaaS) Solutions
  • Infrastructure-as-a-Service (IaaS) Solutions
  • Single-Sign-On (SSO)
  • Vendor Audit

1-Hour Lunch Break

Afternoon Session:

  • Artificial Intelligence (AI)
  • Machine Learning (ML)
  • Large Language Models (LLMs), including ChatGPT
  • Retrieval-Augmented Generation (RAG)
  • Recursive Language Models (RLMs)

15-Minute Break

  • FDA Regulatory Compliance
  • Current FDA Regulatory Enforcement Trends
  • FDA Inspection Types
  • Internal Audit
  • Industry Best Practices

15-Minute Q&A

Who Will Benefit

Personnel in the following roles will benefit:

  • Information Technology Analysts
  • Information Technology Developers and Testers
  • Software Quality Assurance Professionals
  • QC/QA Managers and Analysts
  • Analytical Chemists
  • Compliance and Audit Managers
  • Laboratory Managers
  • Automation Analysts
  • Manufacturing Specialists and Managers
  • Supply Chain Specialists and Managers
  • Regulatory Affairs Specialists
  • Regulatory Submissions Specialists
  • Risk Management Professionals
  • Clinical Data Analysts
  • Clinical Data Managers
  • Clinical Trial Sponsors
  • Computer System Validation Specialists
  • GMP Training Specialists
Faculty Carolyn Troiano

Faculty Carolyn Troiano 

RiskCortex Compliance & Quality Authority Lead/ Advisor

( 45 + yrs exp.)

Carolyn Troiano has 45+ years of experience in computer system validation in the FDA-regulated industries. She is a consultant advising clients on best industry practices for delivering quality and compliant solutions that incorporate newer technologies.

Carolyn participated in the FDA/industry partnership that developed 21 CFR Part 11.

Carolyn encourages leveraging newer technologies and approaches to validation using Computer Software Assurance (CSA) principles.

Carolyn has spoken at international conferences on validation, Part 11, and data integrity.